Literature DB >> 35461718

Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer.

Arghya Ganguly1, Euna Yoo2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35461718      PMCID: PMC9106916          DOI: 10.1016/j.tips.2022.03.011

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   17.638


× No keyword cloud information.
  8 in total

1.  AMG 510 First to Inhibit "Undruggable" KRAS.

Authors: 
Journal:  Cancer Discov       Date:  2019-06-12       Impact factor: 39.397

2.  Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors.

Authors:  Brian A Lanman; Jennifer R Allen; John G Allen; Albert K Amegadzie; Kate S Ashton; Shon K Booker; Jian Jeffrey Chen; Ning Chen; Michael J Frohn; Guy Goodman; David J Kopecky; Longbin Liu; Patricia Lopez; Jonathan D Low; Vu Ma; Ana E Minatti; Thomas T Nguyen; Nobuko Nishimura; Alexander J Pickrell; Anthony B Reed; Youngsook Shin; Aaron C Siegmund; Nuria A Tamayo; Christopher M Tegley; Mary C Walton; Hui-Ling Wang; Ryan P Wurz; May Xue; Kevin C Yang; Pragathi Achanta; Michael D Bartberger; Jude Canon; L Steven Hollis; John D McCarter; Christopher Mohr; Karen Rex; Anne Y Saiki; Tisha San Miguel; Laurie P Volak; Kevin H Wang; Douglas A Whittington; Stephan G Zech; J Russell Lipford; Victor J Cee
Journal:  J Med Chem       Date:  2019-12-24       Impact factor: 7.446

3.  The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Ondrej Fiala; Milos Pesek; Jindrich Finek; Lucie Benesova; Barbora Belsanova; Marek Minarik
Journal:  Cancer Genet       Date:  2013-01-10

4.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Authors:  Jude Canon; Karen Rex; Anne Y Saiki; Christopher Mohr; Keegan Cooke; Dhanashri Bagal; Kevin Gaida; Tyler Holt; Charles G Knutson; Neelima Koppada; Brian A Lanman; Jonathan Werner; Aaron S Rapaport; Tisha San Miguel; Roberto Ortiz; Tao Osgood; Ji-Rong Sun; Xiaochun Zhu; John D McCarter; Laurie P Volak; Brett E Houk; Marwan G Fakih; Bert H O'Neil; Timothy J Price; Gerald S Falchook; Jayesh Desai; James Kuo; Ramaswamy Govindan; David S Hong; Wenjun Ouyang; Haby Henary; Tara Arvedson; Victor J Cee; J Russell Lipford
Journal:  Nature       Date:  2019-10-30       Impact factor: 49.962

5.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors:  Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

6.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

Authors:  Ferdinandos Skoulidis; Bob T Li; Grace K Dy; Timothy J Price; Gerald S Falchook; Jürgen Wolf; Antoine Italiano; Martin Schuler; Hossein Borghaei; Fabrice Barlesi; Terufumi Kato; Alessandra Curioni-Fontecedro; Adrian Sacher; Alexander Spira; Suresh S Ramalingam; Toshiaki Takahashi; Benjamin Besse; Abraham Anderson; Agnes Ang; Qui Tran; Omar Mather; Haby Henary; Gataree Ngarmchamnanrith; Gregory Friberg; Vamsidhar Velcheti; Ramaswamy Govindan
Journal:  N Engl J Med       Date:  2021-06-04       Impact factor: 176.079

7.  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

Authors:  David S Hong; Marwan G Fakih; John H Strickler; Jayesh Desai; Gregory A Durm; Geoffrey I Shapiro; Gerald S Falchook; Timothy J Price; Adrian Sacher; Crystal S Denlinger; Yung-Jue Bang; Grace K Dy; John C Krauss; Yasutoshi Kuboki; James C Kuo; Andrew L Coveler; Keunchil Park; Tae Won Kim; Fabrice Barlesi; Pamela N Munster; Suresh S Ramalingam; Timothy F Burns; Funda Meric-Bernstam; Haby Henary; Jude Ngang; Gataree Ngarmchamnanrith; June Kim; Brett E Houk; Jude Canon; J Russell Lipford; Gregory Friberg; Piro Lito; Ramaswamy Govindan; Bob T Li
Journal:  N Engl J Med       Date:  2020-09-20       Impact factor: 176.079

Review 8.  Sotorasib: First Approval.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2021-09       Impact factor: 9.546

  8 in total
  1 in total

Review 1.  The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine.

Authors:  Qian Wang; Jianlin Han; Alexander Sorochinsky; Aitor Landa; Greg Butler; Vadim A Soloshonok
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.